Soleno Therapeutics, Inc. (SLNO)

Market Cap	4.16B
Revenue (ttm)	32.66M
Net Income (ttm)	-181.08M
Shares Out	52.79M
EPS (ttm)	-3.97
PE Ratio	n/a
Forward PE	91.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,780,037
Open	83.42
Previous Close	81.19
Day's Range	77.73 - 83.42
52-Week Range	41.50 - 90.32
Beta	-2.56
Analysts	Strong Buy
Price Target	110.22 (+40.03%)
Earnings Date	Aug 6, 2025

About PYCR

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwoo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 13, 2014
• Employees: 92
• Stock Exchange: NASDAQ
• Ticker Symbol: SLNO
• Website: https://soleno.life

Analyst Summary

According to 9 analysts, the average rating for SLNO stock is "Strong Buy." The 12-month stock price target is $110.22, which is an increase of 40.03% from the latest price.

Price Target

$110.22

(40.03% upside)

Analyst Consensus: Strong Buy